OKYO Pharma Gains FDA Alignment To Advance Urcosimod

OKYO Pharma received positive feedback from an FDA Type D meeting, validating the regulatory and clinical path forward for Urcosimod in neuropathic corneal pain. The update reduces development uncertainty around FDA alignment, though no efficacy or financial metrics were provided.

Analysis

OKYO Pharma received positive feedback from an FDA Type D meeting, validating the regulatory and clinical path forward for Urcosimod in neuropathic corneal pain. The update reduces development uncertainty around FDA alignment, though no efficacy or financial metrics were provided.